Clinical Research Papers:
Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy
Metrics: PDF 971 views | HTML 2410 views | ?
Qiang Wen1,2, Xue Meng1,2, Peng Xie1,2, Shijiang Wang1,2, Xindong Sun1,2 and Jinming Yu1,2
1Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong University, Jinan, 250117, China
2Shandong Academy of Medical Sciences, Jinan, 250117, China
Jinming Yu, email: email@example.com
Keywords: small cell lung cancer, refractory, platinum-sensitivity status, survival, chemoradiotherapy
Received: January 04, 2017 Accepted: June 27, 2017 Published: July 07, 2017
In this retrospective study, we analyzed the association of clinicopathological factors and therapeutic plans with platinum-sensitivity status and survival of limited-stage small cell lung cancer (LS-SCLC) patients. We enrolled 452 LS-SCLC patients with 279 platinum sensitive and 173 platinum refractory patients. The low serum neuro-specific enolase levels (NSE; p = 0.011), neutrophil-to-lymphocyte ratios (NLR; p = 0.013) and higher objective response rates (p = 0.003) were associated with sensitive group but not the refractory group. Multivariate analysis showed that treatment modality (HR = 0.267, p < 0.001), serum lactate dehydrogenase (LDH; HR = 1.894, p = 0.016), NLR (HR = 2.043, p = 0.043) and platinum-sensitivity status (HR = 0.561, p = 0.036) were independent prognostic factors for survival. We further showed that the numbers of chemotherapy cycles and response to first-line therapy were independent prognostic factors for refractory patients only. Our study demonstrates that platinum-sensitivity status is of prognostic importance, as it is strongly associated with survival in LS-SCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.